Avalo to Present at the H.C. Wainwright 25th Annual Global Investment Conference
06 sept. 2023 07h00 HE
|
Avalo Therapeutics
WAYNE, Pa. and ROCKVILLE, Md., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) announced today that Garry A. Neil, M.D., Chief Executive Officer and Chairman of the Board,...
Avalo Reports Second Quarter 2023 Financial Results and Provides Business Updates
03 août 2023 07h00 HE
|
Avalo Therapeutics
Announced AVTX-002 (quisovalimab) did not meet its primary endpoint in its Phase 2 PEAK Trial in non-eosinophilic asthma, however AVTX-002 significantly reduced serum LIGHT levels for study duration...
Avalo to Participate in SVB Securities Therapeutics Forum
06 juil. 2023 16h01 HE
|
Avalo Therapeutics
WAYNE, Pa. and ROCKVILLE, Md., July 06, 2023 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) announced today that Garry A. Neil, M.D., Chief Executive Officer and Chairman of the Board,...
Avalo Announces Topline Data from Phase 2 PEAK Trial for AVTX-002 (quisovalimab) in Patients with Non-Eosinophilic Asthma
26 juin 2023 07h00 HE
|
Avalo Therapeutics
AVTX-002 did not meet the primary endpoint measured by reduction in asthma related events compared to placebo, although positive trends were observed among a sub-population of patients with elevated...
Avalo to Present at the Jefferies Healthcare Conference
01 juin 2023 07h00 HE
|
Avalo Therapeutics
WAYNE, Pa. and ROCKVILLE, Md., June 01, 2023 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) announced today that Garry A. Neil, M.D., Chief Executive Officer and Chairman of the Board,...
Avalo Announces Appointment of Michael Croft, Ph.D. and Jeff Edelson, M.D. to its Scientific Advisory Board
22 mai 2023 07h00 HE
|
Avalo Therapeutics
Avalo’s SAB is comprised of key opinion leaders in immunology and the LIGHT-signaling network WAYNE, Pa. and ROCKVILLE, Md., May 22, 2023 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq:...
Avalo to Present at ATS 2023 Respiratory Innovation Summit
15 mai 2023 07h00 HE
|
Avalo Therapeutics
WAYNE, Pa. and ROCKVILLE, Md., May 15, 2023 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) announced today that Garry A. Neil, M.D., Chief Executive Officer and Chairman of the Board,...
Avalo to Present at the 2023 RBC Capital Markets Global Healthcare Conference
10 mai 2023 07h00 HE
|
Avalo Therapeutics
WAYNE, Pa. and ROCKVILLE, Md., May 10, 2023 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) announced today that Garry A. Neil, M.D., Chief Executive Officer and Chairman of the Board,...
Avalo Reports First Quarter 2023 Financial Results and Provides Business Updates
04 mai 2023 16h01 HE
|
Avalo Therapeutics
Topline data expected in the second quarter of 2023 from the Phase 2 PEAK Trial of AVTX-002 in non-eosinophilic asthma (NEA)Disclosed cash of approximately $16.7 million as of March 31, 2023 ...
Avalo Reports 2022 Financial Results and Provides Business Updates
29 mars 2023 07h30 HE
|
Avalo Therapeutics
Completed enrollment of the Phase 2 PEAK Trial of AVTX-002 in non-eosinophilic asthma (NEA); topline data expected in the second quarter of 2023Disclosed cash of approximately $13 million as of...